An interventional study of Essence of Chicken (BEC) and Placebo in Biological Age and Essence of Chicken, sponsored by Brand's Suntory Asia. Active, not recruiting at 7 sites in Thailand. Open to participants aged 35 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Brand's Suntory Asia · Not applicable, Interventional, and Other
The goal of this clinical trial is to evaluate the effects of BRAND'S Essence of Chicken (BEC) on biological age. Biological age will be measured using epigenetic clocks [DunedinPACE (primary), GrimAge, PhenoAge, etc] and other relevant tools.
Participants will take BEC or a placebo every day for 1 year. Biological age measures will be taken at baseline and after 1 year.
Brand's Suntory Asia is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
70 ml liquid
Dietary Supplement: Placebo
70 ml liquid
Dietary Supplement: Essence of Chicken (BEC)
Eligible participants will be randomised to receive BEC or placebo for 1 year
Eligible participants will be randomised to receive BEC or placebo for 1 year
Change in biological age (epigenetic age)
DunedinPACE epigenetic clock
Time frame: From baseline to end of intervention (1 year)
Change in biological age (epigenetic age)
GrimAge epigenetic clock
Time frame: From baseline to end of intervention (1 year)
Change in biological age (epigenetic age)
PhenoAge epigenetic clock
Time frame: From baseline to end of intervention (1 year)
Change in biological age (epigenetic age)
Horvath and Hannum epigenetic clock
Time frame: From baseline to end of intervention (1 year)
Change in biological age (epigenetic age)
SYMPHONYAge (SystemsAge of each organ system)
Time frame: From baseline to end of intervention (1 year)
Change in biological age (epigenetic age)
OMICm Age
Time frame: From baseline to end of intervention (1 year)
Change in biological age
Immune Cell Deconvolution
Time frame: From baseline to end of intervention (1 year)
Change in biological age
Telomere
Time frame: From baseline to end of intervention (1 year)
Change in biological age based on composite biomarker approach
Published algorithm derived from clinical blood chemistries
Time frame: From baseline to end of intervention (1 year)
Epigenome-wide association study (EWAS)
Time frame: From baseline to end of intervention (1 year)
Change in quality of life (RAND-36)
RAND 36-Item Health Survey (RAND-36). Scores range from 0 to 100. Higher values mean a more favorable health state.
Time frame: From baseline to end of intervention (1 year)
Change in self-reported cognitive function
PROMIS Cognitive Function - Abilities-Short Form 8a. Raw scores range from 8 to 40. Raw Score will be converted to a standardized PROMIS T-score. Higher T-scores represent better cognitive function/abilities
Time frame: From baseline to end of intervention (1 year)
Change in blood inflammatory marker level
C Reactive Protein (hsCRP)
Time frame: From baseline to end of intervention (1 year)
Change in blood inflammatory marker level
Erythrocyte Sedimentation Rate (ESR)
Time frame: From baseline to end of intervention (1 year)
Change in blood inflammatory marker level
Interleukin 6 (IL 6)
Time frame: From baseline to end of intervention (1 year)
Change in blood oxidative marker level
Malondialdehyde (MDA)
Time frame: From baseline to end of intervention (1 year)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brand's Suntory Asia